SCHEMBL3548552

SCHEMBL3548552

O=C(O)Cc1ccn[c]c1C1CCCCC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 8/20 0.35
KDM4E B2RXH2 2/20 0.34
GLA P06280 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HIF1A Q16665 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP1A2 P05177 1/20 0.33
MAPT P10636 1/20 0.33
USP2 O75604 1/20 0.33
POLB P06746 1/20 0.33
CYP19A1 P11511 1/20 0.33
HAO1 Q9UJM8 1/20 0.33
THRB P10828 1/20 0.32
PTGDR Q13258 3/20 0.32
CCNE1 P24864 1/20 0.32
CDK2 P24941 1/20 0.32
CDK5 Q00535 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15416269 0.77 ACMSD (0.43) KDM4EGLAHTTKMT2ASMN1; SMN2
SCHEMBL3542555 0.75 AKR1B1 (0.40) PTGDR2KDM4ETDP1CYP1A2MAPT
SCHEMBL3545188 0.73 AKR1B1 (0.41) PTGDR2KDM4ETDP1CYP1A2MAPT
SCHEMBL3548297 0.71 FABP3 (0.34) KDM4EKMT2ASMN1; SMN2TDP1L3MBTL1
SCHEMBL18132189 0.69 AOC1 (0.35)
SCHEMBL2550680 0.67 PTGDR2 (0.56) PTGDR2TDP1THRBPTGDRPTGER2
SCHEMBL11147061 0.66 PTGDR2 (0.38) PTGDR2HTTHAO1THRBPTGDR
Hydrochloric Acid SCHEMBL11528572 0.66 PTGDR2 (0.55) PTGDR2TDP1THRBPTGDRPTGER2
SCHEMBL3633503 0.65 PTGDR2 (0.54) PTGDR2TDP1PTGDREPHX2
SCHEMBL11389386 0.65 ACMSD (0.58) PTGDR2KDM4EGLAHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US claimed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US claimed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP claimed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO claimed
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 PTGDR2 663/4885KDM4E 3511/4885GLA 813/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 PTGDR2 648/4885KDM4E 3382/4885GLA 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.